Bristol Myers Squibb (CGT Mfg)

Bothell, WA · Warren, NJ
CAR-T Cell Therapy
567 confirmed programs · 220 sponsors · Last scored 2026-03-15
73.0
Signal Score
✓ FDA Inspections (5) ✓ Clinical Trials (567) ○ SEC Filings ○ Press

Quick Facts: Bristol Myers Squibb (CGT Mfg)

Signal Score
73.0/100 (as of 2026-03-15)
Quality Compliance
Assessment pending
Headquarters
Bothell, WA · Warren, NJ
Modalities
CAR-T, Cell Therapy
Active CGT Programs
567 confirmed from ClinicalTrials.gov across 220 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA Inspections5 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2025-07-18)
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs 567
Sponsors220
ModalitiesCAR-T, Cell Therapy
567 active programs across 220 sponsors
Modalities: CAR-T, Cell Therapy
411 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07388277 CC-97540 in Patients With Antineutrophil Cytoplasmic... PHASE1/PHASE2 Not Yet Recruiting
NCT07361510 A Study to Evaluate the Efficacy of Pumitamig Versus... PHASE3 Not Yet Recruiting
NCT07361497 A Study to Evaluate Pumitamig Versus Durvalumab Following... PHASE3 Not Yet Recruiting
NCT07333261 Study of BMS-986453 in Newly Diagnosed Multiple Myeloma PHASE1 Recruiting
NCT07465029 A Study of Incidence, Treatment Patterns, and Outcomes in... NA Active Not Recruiting
NCT07100080 Study of Izalontamab Brengitecan (BMS-986507) Versus... PHASE2/PHASE3 Recruiting
NCT06855771 A Study of BMS-986504 in Participants With Pre-treated... PHASE2 Recruiting
NCT07018752 A Platform Trial Evaluating New Drugs or Combination in R/R... PHASE1/PHASE2 Recruiting
NCT07105059 A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma PHASE1 Recruiting
NCT06767956 Golcadomide and Nivolumab in Patients With Non-Hodgkin... PHASE1/PHASE2 Not Yet Recruiting
View all 567 programs →
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Financial Stability 83.0
Publicly traded — financial transparency
Source: SEC EDGAR, press monitoring
Subsidiary of Bristol Myers Squibb
SEC FilingsParent: Bristol Myers Squibb
Publicly traded — financial transparency
Capacity 63.0
3 CGT manufacturing sites
Sites: Bothell, WA, Warren, NJ, Devens, MA
Source: SEC EDGAR, press monitoring, company profiles
3 CGT manufacturing sites
3 CGT manufacturing sites

FDA Inspection History

2025-07
2025-07
2024-12
2024-09
2024-09
NAI VAI OAI
Date Site Type Observations Classification
2025-07-18 Summit, New Jersey Human Cellular, Tissue, and Gene Therapies No Voluntary Action Indicated (VAI)
2025-07-08 Devens, Massachusetts Drug Quality Assurance No Voluntary Action Indicated (VAI)
2024-12-06 Summit, New Jersey Bioresearch Monitoring Yes Voluntary Action Indicated (VAI)
2024-09-24 Bothell, Washington Human Cellular, Tissue, and Gene Therapies No No Action Indicated (NAI)
2024-09-06 Summit, New Jersey Bioresearch Monitoring No No Action Indicated (NAI)
Source: FDA Data Dashboard · Retrieved Mar 20, 2026

Clinical Activity 567 studies

NCT07388277 CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis PHASE1/PHASE2 Not Yet Recruiting NCT07361510 A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in... PHASE3 Not Yet Recruiting NCT07361497 A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent... PHASE3 Not Yet Recruiting NCT07333261 Study of BMS-986453 in Newly Diagnosed Multiple Myeloma PHASE1 Recruiting NCT07465029 A Study of Incidence, Treatment Patterns, and Outcomes in... NA Active Not Recruiting NCT07100080 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for... PHASE2/PHASE3 Recruiting NCT06855771 A Study of BMS-986504 in Participants With Pre-treated Advanced or... PHASE2 Recruiting NCT07018752 A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral... PHASE1/PHASE2 Recruiting NCT07105059 A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma PHASE1 Recruiting NCT06767956 Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With... PHASE1/PHASE2 Not Yet Recruiting NCT07141563 A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in... NA Completed NCT06094842 Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific... PHASE1 Withdrawn NCT06764771 A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants... PHASE1 Active Not Recruiting NCT06708949 A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs.... PHASE2 Recruiting NCT06773910 BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage... PHASE2 Recruiting NCT06523621 Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel PHASE2 Recruiting NCT06646276 A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+... PHASE3 Recruiting NCT06697197 A Study of BMS-986482 Alone or as Combination Therapy in Participants With... PHASE1/PHASE2 Recruiting NCT06712355 Safety and Efficacy of BNT327, an Investigational Therapy in Combination... PHASE3 Recruiting NCT06712316 Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With... PHASE2/PHASE3 Recruiting
+ 547 more studies
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs →